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SUMMARY
Background
It is unclear whether the course of cirrhosis and its prognosis are related to
the amount of collagen in the liver.
Aim
To determine whether ﬁbrosis, assessed by collagen proportionate area
(CPA) in patients with compensated cirrhosis, is associated with the pres-
ence of oesophageal varices, and predict disease decompensation during the
follow-up period.
Methods
We prospectively evaluated 118 consecutive patients with compensated cir-
rhosis to correlate ﬁbrosis, assessed by CPA in liver biopsies, with the pres-
ence of oesophageal varices (OV) and with the rate of liver decompensation
(LD) development during a median follow-up of 72 months.
Results
At baseline 38 (32.2%) patients had OV and during the follow-up (median
72 months, IQR 47–91), 17 patients (14.4%) developed LD. The mean CPA
value was different in patients with and without OV (14.8  5.9% vs.
21.6  9.5%, P < 0.001). The best CPA cut-off for OV by area under the
receiver operating characteristic (AUROC) was ≥14% and with multivariate
logistic analysis CPA was the only variable associated with OV (OR: 28.32,
95% CI: 6.30–127.28; P < 0.001). By AUROC analysis the best CPA cut-off
to predict LD was 18.0%. By Cox regression multivariate analysis CPA
≥18% (HR: 3.99, 95% CI: 1.04–11.45; P = 0.036), albumin (HR: 0.12, 95%
CI: 0.04–0.43; P = 0.001) and presence of OV (HR: 8.15, 95% CI: 2.31–
28.78; P = 0.001) were independently associated with LD.
Conclusion
Quantiﬁcation of ﬁbrosis by collagen proportionate area allows identiﬁcation
of patients with compensated HCV cirrhosis with a higher likelihood of
clinically relevant portal hypertension and a higher risk of decompensation.
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INTRODUCTION
Compensated cirrhosis has a wide range of disease sever-
ity,1 including patients with early, histologically proven
cirrhosis, but no clinical evidence of portal hypertension
or signiﬁcant impairment of liver function, as well as
patients with large oesophageal varices and a signiﬁcant
risk of liver decompensation (LD). These patients may
belong to the same Child–Pugh class, but have a differ-
ent short and medium-term prognosis.2 Indeed, 1-year
mortality probability in patients with compensated cir-
rhosis changes according to the presence of oesophageal
varices (OV) ranging from less than 1% per year in
patients without OV (Stage 1) to 3.4% per year in
patients with OV (Stage 2).2
The degree of liver ﬁbrosis is one of the most impor-
tant diagnostic and prognostic assessments in chronic
liver disease. Histological assessment of ﬁbrosis is
regarded as the ‘gold standard’ in this respect. However,
the changes described in the histopathological scoring
categories are largely architectural, with little reference to
the quantity, quality and distribution of ﬁbrosis3, 4 and,
also, current scoring systems only have one ‘stage’ for
cirrhosis and no sub-classiﬁcation is established.4, 5
Moreover, routine ﬁbrosis assessment is usually carried
out on a trichrome or reticulin stain. These are not spe-
ciﬁc collagen stains, and no measurement of the actual
amount of collagen in the liver is made. Computer
assisted digital image analysis (DIA) of picroSirius red
stained histological sections is a method to quantify liver
collagen,3, 6 as the quantity of picroSirius red correlates
well with morphometrically calculated hepatic ﬁbrosis.7
DIA uses segmentation of digital images to measure the
area of collagen and the area of tissue, producing a
‘ﬁbrosis ratio’ or collagen proportionate area (CPA).3 The
reliability of this technique has been recently conﬁrmed
by Huang et al.8 who compared liver CPA determined
by DIA using different staining methods in 249 patients
with chronic hepatitis C. They concluded that CPA using
Sirius red stained biopsies was more accurate for quanti-
fying hepatic collagen compared with trichrome staining.
Furthermore, the study of Pilette et al.9 in 1998, have
shown a better correlation for all serum direct markers
of ﬁbrosis, with the area of ﬁbrosis obtained by image
analysis than with the semi-quantitative score. These
results suggested that image analysis seems to be the
most accurate method for a quantitative approach to
liver ﬁbrosis and for reference for non-invasive methods
of liver ﬁbrosis assessment. In keeping with these results,
other two studies have recently shown a signiﬁcant
correlation of CPA with Liver Stiffness by Transient
Elastography and by PSWE (point shear wave elastogra-
phy technology) in patients with chronic viral hepati-
tis.10, 11
However, CPA evaluation by DIA technique to date
has seldom been used clinically, apart from recent stud-
ies conducted in a cohort of HCV-infected liver trans-
plant recipients followed with serial biopsies.12–15 A
signiﬁcant correlation between CPA and Hepatic Venous
Portal Gradient was demonstrated both in mild-moder-
ate and severe stages of ﬁbrosis suggesting that CPA can
reﬂect a range of disease severity based on collagen con-
tent in this single categorical stage.12–14
Moreover CPA was highly predictive of clinical out-
come in patients infected with hepatitis C virus who
underwent transplantation, better than Ishak stage or
HVPG.13, 14 Finally, analysing changes of CPA in the
serial biopsies of the same setting of patients, Manousou
et al.15 showed that CPA ﬁbrosis progression rate is a
better predictor of clinical outcome than progression by
Ishak stage.
The main aim of this study was to determine whether
ﬁbrosis, assessed by CPA in biopsies from patients with
compensated cirrhosis, was associated to the presence of
clinically signiﬁcant portal hypertension, i.e. oesophageal
varices, and to ﬁrst disease decompensation during the
follow-up period.
PATIENTS AND METHODS
A consecutive cohort of patients with compensated HCV
cirrhosis and an available liver biopsy was prospectively
enrolled at the Liver Unit of the University of Palermo.
All patients gave written informed consent for the use of
clinical data and for the histological evaluation.
Disease management
Liver biopsies were performed using Menghini needles of
16 gauge and were scored by a single pathologist using
METAVIR score.16 Only patients with METAVIR stage
4 were included in the study. On the same week of liver
biopsy, all patients underwent disease assessment includ-
ing the virological evaluation (quantitative HCV-RNA by
reverse transcription-PCR using Cobas Amplicor HCV
Monitor Test, v 2.0; Roche, Basel, Switzerland, and HCV
genotyping by INNO-LiPA HCV II assay; Innogenetics,
Zwijndrecht, Belgium), routine haematology (platelets
and leucocytes count and haemoglobin levels), liver func-
tion tests (bilirubin, albumin, AST and ALT prothrom-
bin time) and renal function tests (serum creatinine).
478 Aliment Pharmacol Ther 2015; 41: 477-486
ª 2015 John Wiley & Sons Ltd
V. Calvaruso et al.
Upper GI endoscopy was performed within 3 months
from histological diagnosis of liver cirrhosis and has
been repeated every 2–3 years as indicated by guide-
lines.17
On serum stored at baseline genotyping for
rs12979860 Single Nucleotide Polymorphism loked was
carried out using the TaqMan SNP genotyping allelic
discrimination method (Applied Biosystems, Foster City,
CA, USA) as reported previously.18
Within not more than 3 months after liver biopsy, all
patients received a course of PEG-IFN plus Ribavirin and
the sustained virological response (SVR) was deﬁned as
undetectable HCV-RNA in serum 24 weeks after stopping
therapy in accordance with international guidelines.19
During the period of observation, the abdominal US
and a control of liver function tests (albumin, prothrom-
bin time and bilirubin) were performed every 6 months.
Biopsy specimen study
For each parafﬁn-embedded liver biopsy sample, the
total length (lengths of each fragment summed) was
recorded and liver biopsies less than 15-mm long were
excluded. The sections of each biopsy stained with pic-
roSirius red were used for DIA which was performed by
one author (V.C.). The equipment setup used consisted
of a digital camera [Canon Powershot A640 (Canon,
Middlesex, UK) attached to a close-up copystand with
backlighting] connected to a compatible personal com-
puter. Calibration of camera setup was: 154 9 154 pix-
els = 23 716 = 1 mm2. After whole section digital image
capture, CPA was measured with Zeiss Axiovision Rel
4.8 (Carl Zeiss, MicriImaging GmbH, Jena, Deutschland)
image analysis software.
The CPA measurement included editing steps to elimi-
nate image artefacts and structural collagen in large portal
tracts (which do not represent disease-related liver ﬁbro-
sis). Unﬁlled natural spaces such as vascular cavities and
lymphoid aggregates were not included in the measure-
ments. The software allows slider adjustment to view the
output overlay at different detection thresholds for binary
(grayscale); or colour (Red, Green, Blue). This method
permits the optimization of the detection overlay by direct
visual comparison with the original picroSirius red image.
We assessed intraobserver variability by repeating the
CPA assessment using 10 biopsies (10% of cohort) ran-
domly selected for a second evaluation by V.C. and inte-
robserver error by using a different observer (D.C.)
unaware of V.C.’s assessments, using a randomly selected
group of 10 biopsies (10% of the cohort). Cohen’s kappa
coefﬁcient has been reported.
Statistical analysis
All data were analyzed using the statistical package SPSS
(version 15.0; SPSS, Chicago, IL, USA). Continuous vari-
ables were summarized as mean and standard deviation
(s.d.), and categorical variables as frequency and percent-
age. Correlation between variables was evaluated by
Spearman correlation. Signiﬁcance testing was two sided
and set to <0.05.
Area under the receiver operating characteristic (AU-
ROC) analysis was used to establish the best cut off
value of CPA to predict the presence of oesophageal var-
ices (OV) and LD.
Logistic regression analysis was used to determine
independent associations with the presence of OV at
baseline. Cox regression analysis was used to evaluate
the variables associated with LD occurrence during the
follow-up. LD was deﬁned as ascites, variceal bleeding
or hepatic encephalopathy. The baseline variables
included in the analysis to determine the association
with the presence of OV were age, gender, serum lev-
els of AST and ALT, platelet count, albumin and bili-
rubin levels, prothrombin activity and CPA and the
variables included in the Cox analysis to determine
the association with the LD were age, gender, serum
levels of AST and ALT, platelet count, albumin and
bilirubin levels, prothrombin activity, CPA, OV and
SVR to anti-viral therapy. The proportion of patients
who experienced LD and the time of the event were
evaluated by Kaplan–Meier curves and log-rank analy-
sis.
A comparison between CPA value in patients who
developed hepatocellular carcinoma (HCC) and who
died during follow-up was performed.
RESULTS
One-hundred and twenty-seven HCV-RNA positive
patients with histological stage 4 by METAVIR score
were included. Seven biopsies were suboptimal (biopsy
length shorter than 15 mm) and in two cases no more
tissue was available to obtain a section for staining with
Sirius red. One hundred and eighteen patients were anal-
ysed. Demographic, clinical and histological features of
patients are shown in Table 1. Average mean of CPA in
the assessable cohort was 17.1  7.9%.
The mean CPA analyzed either in biopsies from 15 to
19 mm in length or those of 20 mm length or longer,
were 17.5% and 16.7% (P = 0.198).
The concordance coefﬁcients between intraobserver
and interobserver evaluation were 0.96 and 0.95 respec-
tively.
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One hundred and two patients had a Child–Pugh
score A 5 and 16 patients had a Child–Pugh score A 6.
Thirty patients (30%) had OV at baseline. Mean CPA
values were signiﬁcantly lower in patients with Child–
Pugh A 5 than Child–Pugh A 6 (16.5  7.2% vs.
20.7  12.4%, P = 0.047).
One hundred and two patients (86.4%), were infected
by HCV genotype 1 and 16 (13.6%) by HCV genotype 2
or 3. Thirty patients (25.4%) obtained a SVR after a
course of anti-viral therapy with Peg-IFN and Ribavirin.
The mean CPA value in patients who obtained SVR was
lower than in non-SVR patients (13.5  5.7% vs.
18.3  8.2%, P = 0.004).
Variables associated with the presence of OV
By univariate analysis, mean CPA was signiﬁcantly dif-
ferent among patients with or without OV (14.8  5.9%
vs. 21.6  9.5%, P < 0.001). By AUROC, the best CPA
cut-off value for OV was 14% (AUROC 0.813, Sensitiv-
ity: 92%; Speciﬁcity: 75%; PPV: 64%; NPV 95%) (Fig-
ure 1a). The rate of patients with CPA ≥14% was
signiﬁcantly higher in the group of patients with OV
(94.7%) than in those without OV (37.5%), P < 0.001.
Platelet counts were marginally related to OV
(128.6 9 109/L  43.2 9 109/L vs. 149.7 9 109/L 
88.4 9 109/L; P = 0.091). By multivariate logistic analysis
CPA ≥14% was the unique variable associated with OV
(OR: 28.32, 95% CI: 6.30–127.28; P < 0.001) (Table 2).
We also verify the role of CPA to predict the presence
of OV in the 88 patients who did not achieve SVR. By
univariate and multivariate analysis CPA ≥14% remained
the unique variable independently related to presence of
OV (OR: 34.58, 95% CI: 4.41–271.42; P = 0.001)
(Table 3).
Analysing the 88 patients who did not have OV at
baseline we observed that mean CPA of patients who
carried on to not have OV during the follow-up was
lower with respect the 31 patients who had developed
OV (13.6  5.6% vs. 15.7  6.6%). However this differ-
ence did not achieve the statistical signiﬁcance
(P = 0.121).
Variables associated with the risk of LD
The median follow-up was 72 months (IQR 47–91). Sev-
enteen patients developed decompensation (12 ascites, 3
EPS and 2 OV bleeding).
By univariate analysis, mean CPA was signiﬁcantly
different among patients with or without development of
LD (23.5  8.0% vs. 15.9  7.5%; P < 0.001) (Table 3).
Also platelet count (107.3 9 109/L  40.0 9 109/L vs.
142.7 9 109/L  44.4 9 109/L; P = 0.003), albumin
(3.7  0.5 vs. 4.2  0.4 g/dL; P < 0.001), presence of
OV (76.5% vs. 24.5%; P < 0.001) and absence of SVR
after anti-viral therapy (94.1% vs. 71.4%; P = 0.043) were
associated with an higher risk of decompensation. By
AUROC analysis, the best CPA cut-off value for decom-
pensation during follow-up was 18.0% (AUROC: 0.815,
Sensitivity: 84%; Speciﬁcity: 78%; PPV: 40%; NPV 97%)
(Figure 1b). By Kaplan–Meyer analysis, we found that
patients with a CPA less than 18.0% had a longer
decompensation-free survival (119.2 months, 95% CI:
113.8–124.8 months) as compared to those with CPA
equal or above 18.0% (90.8 months, 95% CI: 74.9–
106.7 months), Log rank test: P < 0.001 (Figure 2). By
Cox regression multivariate analysis, CPA ≥18% (HR:
3.99, 95% CI: 1.04–11.45; P = 0.036), albumin (HR: 0.12,
95% CI: 0.04–0.43; P = 0.001) and presence of OV (HR:
8.15, 95% CI: 2.31–28.78; P = 0.001) were independently
associated with LD (Table 4).
Table 1 | Demographic, clinical and histological
features of 118 patients with compensated HCV
cirrhosis prospectively evaluated by DIA
Variables Results
Number of patients 118
Age (mean  s.d.) 57.2  9.1
Gender (% males) 68 (57.6)
AST-U/L (mean  s.d.) 112.4  64.9
ALT-U/L (mean  s.d.) 152  91.2
Platelets (9109/L) (mean  s.d.) 143.1  77.6
WBCs (9103/L) (mean  s.d.) 6.18  1749.0
Hb (g/dL) (mean  s.d.) 14.6  1.3
Prothrombin activity (%) (mean  s.d.) 88.7  18.0
Total Bilirubin (mg/dL) (mean  s.d.) 0.9  0.5
Albumin (g/dL) (mean  s.d.) 4.1  0.4
Spleen diameter (cm) (mean  s.d.) 13.7  3.1
Presence of oesophageal varices (%) 38 (32.2)
Presence of large oesophageal varices (%) 2 (1.7)
MHCV genotype (%)
1 102 (86.4)
2–3 16 (13.6)
Genotypes of rs12979860 SNP
C/C (%) 31 (26.3)
T/C or T/T (%) 87 (73.7)
CPA (%) (mean  s.d.) 17.1  7.9
SVR (%) 30 (25.6)
AST, aspartate aminotransferase; ALT, alanine aminotransfer-
ase; WBCs, white blood cells; Hb, haemoglobin; HCV, hepatitis
C virus; CPA, collagen proportionate area; SVR, sustained viro-
logical response.
Quantitative variables are expressed as mean and s.d. and cat-
egorical variables as absolute number with percentage into
brackets.
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The same analysis was also performed among the 88
patients who did not achieve SVR after antiviral therapy.
Similarly to the whole cohort, at the univariate analysis
the variables related to LD were platelets, albumin value,
presence of oesophageal varices and CPA ≥18%. By
multivariate Cox regression analysis, albumin, presence
of OV and CPA ≥18% remained the independent predic-
tors of LD (Table 5).
Area under the receiver operating characteristic analy-
sis of presence of oesophageal varices and albumin value
for LD are shown in Figure S1. For both variables, the
area under the curve is lower than the AUROC of CPA.
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Figure 1 | AUROCs of CPA for diagnosis of OV and Liver decompensation in patients with HCV-related cirrhosis
evaluated by DIA. (a) Receiver operating characteristic (ROC) curve showing the prediction of oesophageal varices
with CPA in patients with HCV-related cirrhosis. The area under the ROC curve is 0.813. (b) Receiver operating
characteristic (ROC) curve showing the prediction of liver decompensation with CPA in patients with HCV-related
cirrhosis. The area under the ROC curve is 0.815.
Table 2 | Variables associated with oesophageal varices (OV) of 118 patients with histological diagnosis of HCV
cirrhosis prospectively evaluated by CPA
Variables
No OV
80 pts (67.8%)
O
38 pts (32.2%)
Univariate analysis
P-value
Multivariate analysis
OR (95% CI) P-value
Age (mean  s.d.) 56.8  9.0 58.1  9.4 0.460 –
Gender (% males) 45 (56.2) 23 (60.5) 0.660 –
Platelets (9109/L, mean  s.d.) 149.7  88.4 128.6  43.2 0.091 0.99 (0.98–1.01) 0.563
AST (IU/L, mean  s.d.) 112.8  65.8 112.0  64.1 0.950 –
ALT (IU/L, mean  s.d.) 159.6  96.2 136.4  83.2 0.225 –
Prothrombin time (%, mean  s.d.) 90.2  14.4 91.7  9.3 0.911 –
Bilirubin (mg/dL, mean  s.d.) 0.9  0.5 0.9  0.5 0.522 –
Albumin (g/dL, mean  s.d.) 4.1  0.5 4.0  0.4 0.122 –
CPA ≥14% 30 (37.5) 36 (94.7) <0.001 28.32 (6.30–127.28) <0.001
Quantitative variables are expressed as mean and standard deviation and categorical variables as absolute number with percent-
age into brackets.
By univariate analysis CPA value is signiﬁcantly associated to presence of OV. The analysis shows a marginal association with
platelets (P < 0.1). By multivariate analysis CPA equal or higher 14% is the unique variables associated with presence of OV.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPA, collagen proportionate area; OV, oesophageal varices; OR,
odds ratio; CI, conﬁdence interval.
Bold data identify the statistical signiﬁcant p values.
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Collagen proportionate area was not associated with
the risk of developing HCC since the mean CPA value
in the eight patients with HCC during follow-up was
comparable to those not developing HCC (18.0  10.8%
vs. 17.0  7.8%, P = 0.729).
During the follow-up 12 patients (10.2%) died. There-
fore, we have performed a Kaplan–Meyer analysis to pre-
dict mortality in this cohort of patients and we have found
that patients with a CPA less than 18.0% had a longer
survival (125.5 months, 95% CI: 119.3–131.7 months) as
compared to those with CPA equal or above 18.0%
(108.3 months, 95% CI: 94.6–122.0 months). This differ-
ence is signiﬁcant by Log rank test: P = 0.025.
DISCUSSION
Quantitative assessment of ﬁbrosis on liver biopsies from
cirrhotic livers by measurement of the CPA allows to
split the prognosis of compensated cirrhosis in different
subclasses. Its correlation with HVPG has been shown in
the setting of post-transplanted HCV patients12 but until
now CPA had not been evaluated in the setting of com-
pensated HCV cirrhosis with the aim to identify its cor-
relation with endoscopic signs of portal hypertension,
and occurrence of LD.
Table 3 | Variables associated with oesophageal varices (OV) of 88 patients with histological diagnosis of HCV
cirrhosis prospectively evaluated by CPA and non-responder to anti-viral therapy with Peg-interferon and Ribavirin
Variables
No OV
56 pts (63.6%)
OV
32 pts (36.4%)
Univariate analysis
P-value
Multivariate analysis
OR (95% CI) P-value
Age (mean  s.d.) 56.6  9.2 58.5  9.0 0.362 –
Gender (% males) 31 (55.4) 18 (56.3) 0.992 –
Platelets (9109/L, mean  s.d.) 135.0  38.7 120.9  38.3 0.104 –
AST (IU/L, mean  s.d.) 107.6  57.1 114.0  67.5 0.652 –
ALT (IU/L, mean  s.d.) 145.2  81.7 139.2  82.4 0.761 –
Prothrombin time (%, mean  s.d.) 89.0  14.0 92.4  9.5 0.220 –
Bilirubin (mg/dL, mean  s.d.) 0.9  0.4 0.9  0.4 0.605 –
Albumin (g/dL, mean  s.d.) 4.1  0.4 4.0  0.4 0.166 –
CPA ≥ 14% 26 (46.4) 31 (96.9) <0.001 34.58 (4.41–271.42) 0.001
Quantitative variables are expressed as mean and standard deviation and categorical variables as absolute number with percent-
age into brackets.
Both univariate and multivariate analysis show that CPA equal or higher 14% is the unique variables associated with presence of
OV.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPA, collagen proportionate area; OV, oesophageal varices; OR,
odds ratio; CI, conﬁdence interval.
Bold in all tables identify the statistical signiﬁcant p values.
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Figure 2 | Incidence of Liver Decompensation in
patients with HCV cirrhosis according to CPA value.
Cumulative incidence of ﬁrst episode of liver
decompensation (LD) in patients with CPA lower than
18% (continuous line) and in patients with CPA ≥18%
(dashed line), By Kaplan–Meyer analysis, the patients
with a CPA less than 18.0% had a longer
decompensation-free survival (119.2 months, 95% CI:
113.8–124.8 months) as compared to those with CPA
equal or above 18.0% (90.8 months, 95% CI: 74.9–
106.7 months), log rank test: P < 0.001.
482 Aliment Pharmacol Ther 2015; 41: 477-486
ª 2015 John Wiley & Sons Ltd
V. Calvaruso et al.
Our study, performed in a referral centre for the treat-
ment and management of patients with chronic liver
disease, have evaluated the CPA in a homogeneous
cohort of patients with histological diagnosis of HCV
compensated cirrhosis. Thirty-two percent of patients
had oesophageal varices and 14.4% developed LD. Our
results show that there is a higher CPA value in patients
with Child–Pugh A6 than A5 demonstrating a better
discriminative ability of CPA to differentiate between
these two close classes of prognosis. Furthermore, a sig-
niﬁcant CPA difference was shown between patients with
and without OV and the multivariate logistic analysis
showed that CPA was the sole variable independently
associated to the presence of OV. The CPA cut-off of
14% had a high sensitivity and negative predictive value
to diagnose OV. This evidence conﬁrms the direct corre-
lation between CPA and portal hypertension suggesting
its ability to identify different classes within the stage of
compensated cirrhosis.
Moreover, liver CPA in the baseline biopsy was corre-
lated with the occurrence of decompensation during a
median follow-up of 72 months, and in particular the
best cut off value of 18% of CPA was related to a higher
risk of LD together with albumin values and presence of
OV. The strength of this association was conﬁrmed by
the absence of SVR between the variables independently
associated with LD, suggesting that patients with less
ﬁbrosis have a lower risk to develop decompensation in
the short term regardless of the virological outcome of
treatment. Thus, our data suggest that CPA is better
than semiquantitative histological scores which are not
able to describe beyond cirrhosis. CPA will be useful to
stratify the risk of decompensation in cirrhosis, and help
to chose and allocate patients correctly for anti-viral
therapy. This may become particularly relevant at a time
when ‘informed deferral’ of therapy is increasingly being
considered in these patients in the wake of high expecta-
tions for IFN free regimens.20 In the past years, many
studies investigating risk factors for disease progression
in patients with CHC have been performed and Koner-
man et al. have systematically summarised the results in
a single document.21
The conclusion of this review demonstrated that even
if a lot of studies have identiﬁed the factors associated
with histological and/or clinical progression in CHC
(platelets count, bilirubin, albumin, liver steatosis, etc.),
we need to analyze cohorts of more characterised
patients and follow them for a sufﬁciently long duration
to can develop prediction models. Furthermore, no stud-
ies using CPA as predictor of disease progression have
Table 4 | Risk factors for liver decompensation (LD) by Cox multivariate model in 118 patients with biopsy proven
HCV cirrhosis, prospectively evaluated by CPA
No LD
98 pts* (85.6%)
LD
17 pts (14.4%)
Univariate analysis
P-value
Multivariate analysis
HR (95% CI) P-value
Age (years, mean  s.d.) 56.5  9.4 60.0  7.2 0.148 –
Gender (% males) 58 (59.1) 7 (41.1) 0.153 –
Platelets (9109/L, mean  s.d.) 142.7  44.4 107.3  40.0 0.003 1.00 (0.98–1.02) 0.223
AST (IU/L, mean  s.d.) 113.2  67.1 108.8  53.2 0.800
ALT (IU/L, mean  s.d.) 155.2  94.1 133.6  72.2 0.389
Prothrombin time (%, mean  s.d.) 90.2  13.3 93.7  10.4 0.325
Bilirubin (mg/dL, mean  s.d.) 0.9  0.4 1.0  0.5 0.258
Albumin (g/dL, mean  s.d.) 4.2  0.4 3.7  0.5 <0.001 0.12 (0.04–0.43) 0.001
CPA ≥18% (%) 28 (28.6) 14 (82.3) <0.001 3.99 (1.04–11.45) 0.036
Presence of oesophageal varices (%) 24 (24.5) 13 (76.5) <0.001 8.15 (2.31–28.78) 0.001
No SVR (%) 70 (71.4) 16 (94.1) 0.043 3.68 (0.40–38.05) 0.244
Quantitative variables are expressed as mean and standard deviation and categorical variables as absolute number with percent-
age into brackets.
By univariate Cox analysis platelet count, albumin value, CPA ≥18%, presence of OV and absence of virological response are
associated with development of LD (all P < 0.05). The independent predictors of LD in the whole cohort of patients are albumin
value, CPA ≥18% and presence of OV (all P < 0.05 by multivariate Cox regression analysis).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPA, collagen proportionate area; SVR, sustained virological
response; LD, liver decompensation; OR, odds ratio; CI, conﬁdence interval.
* Three patients dropped out during follow-up.
Bold in all tables identify the statistical signiﬁcant p values.
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been analyzed, therefore our study which enrolled an
homogenous cohort of patient with a single aetiology of
compensated cirrhosis, followed up for long time may be
helpful to evaluate the prognostic role of this new pre-
dictor of clinical progression. Similarly, till now a sys-
tematic assessment of the available data about the role of
non-invasive imaging modalities and risk of decompen-
sation has not been performed. Robic et al.22 have dem-
onstrated that liver stiffness by TE is effective as HVPG
in predicting clinical decompensation in patients with
chronic liver disease. Moreover, in the last years, also
liver stiffness measured by magnetic resonance elastogra-
phy has been associated both with advanced ﬁbrosis23
and LD24 in patients with chronic liver disease proving
the ability of these techniques in sub-classify liver cirrho-
sis similarly to CPA. Furthermore, the ﬁrst two stud-
ies.10, 11 which have correlated liver stiffness value with
CPA have found a signiﬁcant correlation between the
two parameters suggesting that a quantitative measure-
ment of liver ﬁbrosis as CPA could represent a better
reference for non-invasive methods of liver ﬁbrosis
assessment. The risk of developing HCC was not associ-
ated with CPA. This result was not unexpected. Indeed,
in a larger cohort of clinical or histological proven HCV
patients with cirrhosis enrolled in our centre, we had
already observed that the variables related to portal
hypertension and liver function (presence of OV, platelet
count, albumin value) did not inﬂuence the rate of devel-
opment of HCC,25 which seems to be related to other
variables including age, gender and liver necroinﬂamma-
tion. Moreover, we did not ﬁnd a signiﬁcant difference
in CPA values between patients who developed de novo
varices, during follow-up or not. A possible explanation
of this result could be the high percentage of very early
stage of cirrhosis in patients who underwent liver biopsy.
Indeed, in comparison with data from literature,2, 26 we
observed a lower rate of decompensation in the whole
cohort (2.4% per year) and in the group of patients with-
out OV (0.8% per year). This is most likely due to a
selection bias, as all patients underwent liver biopsy to
diagnose cirrhosis, especially because clear clinical signs
of liver cirrhosis were not evident at baseline. Also the
absence of signiﬁcant correlation between platelet count
and OV at multivariate analysis suggests a selection of a
cohort with very early cirrhosis which is one limitation
of this study.
A larger cohort of patient with cirrhosis and clinical
evidence of portal hypertension (possibly using biopsies
Table 5 | Risk factors for liver decompensation (LD) by Cox multivariate model in 88 patients with biopsy proven
HCV cirrhosis, prospectively evaluated by CPA and without response to anti-viral therapy with Peg-interferon and
Ribavirin
No LD
71 pts* (81.8%)
LD
16 pts (18.2%)
Univariate analysis
P-value
Multivariate analysis
HR (95% CI) P-value
Age (years, mean  s.d.) 56.6  9.5 60.1  7.2 0.173 –
Gender (% males) 42 (59.2) 7 (43.8) 0.160 –
Platelets (9109/L, mean  s.d.) 135.3  37.2 107.1  38.8 0.003 0.99 (0.97–1.01) 0.246
AST (IU/L, mean  s.d.) 110.4  63.0 109.0  52.9 0.928
ALT (IU/L, mean  s.d.) 145.2  84.0 133.9  72.2 0.617
Prothrombin time (%, mean  s.d.) 89.4  13.0 93.1  10.4 0.236
Bilirubin (mg/dL, mean  s.d.) 0.8  0.3 1.0  0.4 0.261
Albumin (g/dL, mean  s.d.) 4.1  0.4 3.7  0.5 <0.001 0.06 (0.01–0.27) <0.001
CPA ≥18% (%) 23 (32.4) 14 (87.5) <0.001 4.82 (1.28–18.16) 0.020
Presence of oesophageal varices (%) 19 (26.8) 13 (81.3) 0.007 13.9 (3.15–61.29) 0.001
Quantitative variables are expressed as mean and standard deviation and categorical variables as absolute number with percent-
age into brackets.
In patients who did not achieve SVR, platelet count, albumin value, CPA ≥18%, and presence of OV are associated with LD
(P < 0.05 by univariate Cox analysis). The factors independently associated with LD by multivariate Cox regression analysis, are
albumin value, CPA ≥18% and presence of OV (all P < 0.05).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPA, collagen proportionate area; LD, liver decompensation; OR,
odds ratio; CI, conﬁdence interval.
* One no SVR patient dropped out during follow-up.
Bold in all tables identify the statistical signiﬁcant p values.
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taken by a transjugular route) would represent an inter-
esting setting to further elaborate on our data and to fur-
ther explore the prognostic role of CPA.
In conclusion, our study has conﬁrmed that CPA
measurement by DIA is a simple technique which can
be used together with semiquantitative histological evalu-
ation to better assess liver ﬁbrosis and prognosis of
patients with cirrhosis as well as chronic liver disease.
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